News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Neos Therapeutics (NEOS) To Participate In Three September Conferences

8/30/2017 8:32:04 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
FORT WORTH, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer will present a business overview and update at the following two upcoming September conferences:

  • Wells Fargo 2017 Healthcare Conference at 3:00 p.m. E.T. on Wednesday, September 6, 2017 in Boston, MA

  • Cantor Fitzgerald Global Healthcare Conference at 8:35 a.m. E.T. on Tuesday, September 26, 2017 in New York, NY

A live audio webcast of both events will be available on the Investor Relations page of the company’s website at An archived replay of the webcast will be available for 30 days after the live event concludes.

Neos management will also be available for one-on-one meetings at the Mizuho Biotechnology Conference 2017 on Tuesday, September 19, 2017 in Boston, MA.

About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT®, indicated for the treatment of ADHD in patients 6 years of age and older, and Cotempla XR-ODTTM, indicated for the treatment of ADHD in patients 6 to 17 years old, are the first approved products using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for one other branded product candidate that is an XR medication in oral suspension dosage form. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200

Read at

Related News

comments powered by Disqus